Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.

Autor: Weaver AN; University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA., Iams WT; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA., Park JC; Massachusetts General Hospital, Boston, Massachusetts, USA., Mita M; Cedars-Sinai Medical Center, Los Angeles, California, USA., Holtick U; Department of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, North Rhine-Westphalia, Germany., Gordon MS; Pinnacle Oncology Hematology, Arizona Center for Cancer Care, HonorHealth Research Institute Clinical Trials Program, Virginia G. Piper Cancer Center, Scottsdale, Arizona, USA., Rodabaugh KJ; University of Nebraska Medical Center, Omaha, Nebraska, USA., Dhani N; University Health Network Princess Margaret Cancer Centre, Toronto, Canada., Neupane P; University of Kansas Cancer Center, Fairway, Kansas, USA., Taylor M; Earle A. Chiles Research Institute, Portland, Oregon, USA., Amanda Duvall E; SQZ Biotechnologies, Watertown, Massachusetts, USA., Jennings J; SQZ Biotechnologies, Watertown, Massachusetts, USA., Miselis NR; SQZ Biotechnologies, Watertown, Massachusetts, USA., Loughhead S; SQZ Biotechnologies, Watertown, Massachusetts, USA., Warren MS; SQZ Biotechnologies, Watertown, Massachusetts, USA., Bernstein H; SQZ Biotechnologies, Watertown, Massachusetts, USA., Klussmann JP; Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, North Rhine-Westphalia, Germany., Baranda J; University of Kansas Cancer Center, Fairway, Kansas, USA., Jimeno A; University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA.

Publikováno v: Molecular carcinogenesis [Mol Carcinog] 2024 Aug; Vol. 63 (8), pp. 1421-1428. Date of Electronic Publication: 2024 May 02.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Autor: Moschos SJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Sullivan RJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Hwu WJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ramanathan RK; Translational Genomics Research Institute, Phoenix, Arizona, USA; Virginia G. Piper Cancer Center, Scottsdale, Arizona, USA., Adjei AA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA., Fong PC; The University of Auckland and Auckland City Hospital, Auckland, New Zealand., Shapira-Frommer R; Department of International Medicine, Chaim Sheba Medical Center, Tel-HaShomer, Israel., Tawbi HA; University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA., Rubino J; Merck & Co. Inc., Kenilworth, New Jersey, USA., Rush TS 3rd; Merck & Co. Inc., Kenilworth, New Jersey, USA., Zhang D; Merck & Co. Inc., Kenilworth, New Jersey, USA., Miselis NR; Merck & Co. Inc., Kenilworth, New Jersey, USA., Samatar AA; Merck & Co. Inc., Kenilworth, New Jersey, USA., Chun P; Merck & Co. Inc., Kenilworth, New Jersey, USA., Rubin EH; Merck & Co. Inc., Kenilworth, New Jersey, USA., Schiller J; Merck & Co. Inc., Kenilworth, New Jersey, USA., Long BJ; Merck & Co. Inc., Kenilworth, New Jersey, USA., Dayananth P; Merck & Co. Inc., Kenilworth, New Jersey, USA., Carr D; Merck & Co. Inc., Kenilworth, New Jersey, USA., Kirschmeier P; Merck & Co. Inc., Kenilworth, New Jersey, USA., Bishop WR; Merck & Co. Inc., Kenilworth, New Jersey, USA., Deng Y; Merck & Co. Inc., Kenilworth, New Jersey, USA., Cooper A; Merck & Co. Inc., Kenilworth, New Jersey, USA., Shipps GW; Merck & Co. Inc., Kenilworth, New Jersey, USA., Moreno BH; Jonsson Comprehensive Cancer Center at UCLA, University of California Los Angeles, Los Angeles, California, USA., Robert L; Jonsson Comprehensive Cancer Center at UCLA, University of California Los Angeles, Los Angeles, California, USA., Ribas A; Jonsson Comprehensive Cancer Center at UCLA, University of California Los Angeles, Los Angeles, California, USA., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

Publikováno v: JCI insight [JCI Insight] 2018 Feb 22; Vol. 3 (4). Date of Electronic Publication: 2018 Feb 22 (Print Publication: 2018).

Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma.

Autor: Miselis NR, Lau BW, Wu Z, Kane AB

Publikováno v: Cancer microenvironment : official journal of the International Cancer Microenvironment Society [Cancer Microenviron] 2010 Jun 22; Vol. 4 (1), pp. 39-50. Date of Electronic Publication: 2010 Jun 22.

Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma.

Autor: Miselis NR; Department of Pathology and Laboratory Medicine, Brown University, Box G-E531, Providence, RI 02912, USA. Nathan_Miselis@brown.edu, Wu ZJ, Van Rooijen N, Kane AB

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2008 Apr; Vol. 7 (4), pp. 788-99. Date of Electronic Publication: 2008 Mar 28.